Ophthalmology

Prostaglandin F2α (PGF2α) drives luteolysis and smooth muscle contraction by activating the FP receptor.

17-phenyl trinor Prostaglandin F2α N-ethyl amide (17-phenyl trinor PGF2α) is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug, sold under the Allergan trade name 17-phenyl trinor PGF2α ethyl amide.

17-phenyl trinor Prostaglandin F2α (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α and is a potent agonist for the FP receptor.

(±)17-HDHA is an autoxidation product of docosahexaenoic acid in vitro.

Latanoprost is an F-series prostaglandin (PG) analog which has been approved for use as an ocular hypotensive drug.

17-phenyl trinor Prostaglandin F2α (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α with potent FP receptor agonist activity and well known intraocular pressure-reducing effects.

Prostaglandin F2α ethanolamide (PGF2α-EA) is produced by cyclooxygenase 2 (COX-2) metabolism of the endogenous cannabinoid, arachidonoyl ethanolamide, found in brain, liver, and other mammalian tissues.

Fluprostenol isopropyl ester is a potent F-series prostaglandin receptor agonist prodrug that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma.

Fluprostenol isopropyl ester is a potent F-series prostaglandin receptor agonist prodrug that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma.

15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α isopropyl ester) is the latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15.

Fluprostenol is an F-series prostaglandin analog which has been approved for many years as a luteolytic in veterinary animals.

Bimatoprost is the Allergan trade name for 17-phenyl trinor prostaglandin F2α ethyl amide (17-phenyl trinor PGF2α ethyl amide), an F-series PG analog which has been approved for use as an ocular hypotensive drug.

The actions of many clinical F-series prostaglandins (PGs), including those used for estrous synchronization and for reduction of intraocular pressure (IOP), are mediated through the PGF2α (FP) receptor.

Prostaglandin F2α (PGF2α) drives luteolysis and smooth muscle contraction by activating the FP receptor.

Prostaglandin F2α (PGF2α) drives luteolysis and smooth muscle contraction by activating the FP receptor.

The actions of many clinical F-series prostaglandins (PGs), including those used for estrous synchronization and reduction of intraocular pressure (IOP), are mediated through the PGF2α (FP) receptor.

17-phenyl trinor Prostaglandin F2α amide is a N-desethyl metabolite of Bimatoprost.

17-phenyl trinor Prostaglandin F2α cyclopropyl amide (17-phenyl trinor PGF2α cyclopropyl amide) is a novel analog of 17-phenyl trinor PGF2α ethyl amide.

Prostaglandin F2α (PGF2α) activates the FP receptor, promoting smooth muscle contraction and luteolysis.

17-phenyl trinor Prostaglandin F2α diethyl amide (17-phenyl trinor PGF2α diethyl amide) is an analog of PGF2α in which the C-1 carboxyl group has been modified to an N-diethyl amide.

17-phenyl trinor PGF2α N-ethyl amide is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug, sold under the Allergan trade name Bimatoprost.

17-phenyl trinor Prostaglandin F2α (17-phenyl trinor PGF2α) is a metabolically stable analog of PGF2α and is a potent agonist for the FP receptor, binding with a relative potency of 756% compared to that of PGF2α.

A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma.

Prostaglandin F2α (PGF2α), acting through the FP receptor, causes smooth muscle contraction and exhibits potent luteolytic activity.